Proactive Investors - Run By Investors For Investors

Hikma sounds the earnings alarm sending shares crashing

A tough and competitive market hit the firm's Generics business
Hikma sounds the earnings alarm sending shares crashing
Hikma certainly wasn't the investment to be in this morning!

Shares in Hikma Pharmaceuticals (LON:HIK) were marked down 7% after the company lowered guidance for sales of generic products and warned of an “increasingly challenging environment”.

The competition in this particular arena has meant the company has been forced progressively chop back its revenue estimate for the unit, which now stands at US$620mln for the year; in April the figure was US$800mln.

Total revenues are set to be in the order of US$2bn.

Interim results from the FTSE 250 ‘druggie’, which also specialises in injectable products, were lacklustre with sales up 1% at US$895mln, bit operating profits off US$8mln at US$113mln.

Tough market

“In the US, where competition is increasing and pricing pressure is intensifying, sales in our Injectables business were resilient and we maintained our track record of strong profitability,” said chairman Said Darwazah.

“The tougher market conditions did however continue to limit growth in our Generics business. 

“We remain focused on executing our Generics strategy and we have strengthened the management team and further restructured the cost base to provide a robust and efficient platform to support pipeline execution and future growth.”

The shares, off 35% in the year to date, fell 95.96p to 1,227p, valuing the business at just under £3bn.

Strenghens Takeda ties

Separately, Hikma said it has strengthened ties with Japanese giant Takeda by expanding its licensing and distribution agreement in the Middle East and North Africa (MENA).

The two will focus their expertise on promoting cardiovascular and diabetes treatments, according to Mazen Darwazah, the company’s head of emerging markets.  

“We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region,” he added.

“By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines."

View full HIK profile View Profile

Hikma Pharmaceuticals Timeline

Related Articles

Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use